Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

Glucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular proteins in the ER lumen, maintaining calcium homeo...

Full description

Bibliographic Details
Main Authors:	Ji Woong Kim, Yea Bin Cho, Sukmook Lee
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cells
Subjects:	GRP94 cancer therapeutic target therapy monoclonal antibody
Online Access:	https://www.mdpi.com/2073-4409/10/3/670

id	doaj-796ab600e9a44ef5a6ee7871d3977b0e
record_format	Article
spelling	doaj-796ab600e9a44ef5a6ee7871d3977b0e2021-03-18T00:05:39ZengMDPI AGCells2073-44092021-03-011067067010.3390/cells10030670Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer TherapyJi Woong Kim0Yea Bin Cho1Sukmook Lee2Biopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, Seoul 02707, KoreaBiopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, Seoul 02707, KoreaBiopharmaceutical Chemistry Major, School of Applied Chemistry, Kookmin University, Seoul 02707, KoreaGlucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular proteins in the ER lumen, maintaining calcium homeostasis, and modulating immune system function. Recently, several reports have shown the functional role and clinical relevance of GRP94 overexpression in the progression and metastasis of several cancers. Therefore, the current review highlights GRP94’s physiological and pathophysiological roles in normal and cancer cells. Additionally, the unmet medical needs of small chemical inhibitors and the current development status of monoclonal antibodies specifically targeting GRP94 will be discussed to emphasize the importance of cell surface GRP94 as an emerging therapeutic target in monoclonal antibody therapy for cancer.https://www.mdpi.com/2073-4409/10/3/670GRP94cancertherapeutic targettherapymonoclonal antibody
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Ji Woong Kim Yea Bin Cho Sukmook Lee
spellingShingle	Ji Woong Kim Yea Bin Cho Sukmook Lee Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy Cells GRP94 cancer therapeutic target therapy monoclonal antibody
author_facet	Ji Woong Kim Yea Bin Cho Sukmook Lee
author_sort	Ji Woong Kim
title	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
title_short	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
title_full	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
title_fullStr	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
title_full_unstemmed	Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy
title_sort	cell surface grp94 as a novel emerging therapeutic target for monoclonal antibody cancer therapy
publisher	MDPI AG
series	Cells
issn	2073-4409
publishDate	2021-03-01
description	Glucose-regulated protein 94 (GRP94) is an endoplasmic reticulum (ER)-resident member of the heat shock protein 90 (HSP90) family. In physiological conditions, it plays a vital role in regulating biological functions, including chaperoning cellular proteins in the ER lumen, maintaining calcium homeostasis, and modulating immune system function. Recently, several reports have shown the functional role and clinical relevance of GRP94 overexpression in the progression and metastasis of several cancers. Therefore, the current review highlights GRP94’s physiological and pathophysiological roles in normal and cancer cells. Additionally, the unmet medical needs of small chemical inhibitors and the current development status of monoclonal antibodies specifically targeting GRP94 will be discussed to emphasize the importance of cell surface GRP94 as an emerging therapeutic target in monoclonal antibody therapy for cancer.
topic	GRP94 cancer therapeutic target therapy monoclonal antibody
url	https://www.mdpi.com/2073-4409/10/3/670
work_keys_str_mv	AT jiwoongkim cellsurfacegrp94asanovelemergingtherapeutictargetformonoclonalantibodycancertherapy AT yeabincho cellsurfacegrp94asanovelemergingtherapeutictargetformonoclonalantibodycancertherapy AT sukmooklee cellsurfacegrp94asanovelemergingtherapeutictargetformonoclonalantibodycancertherapy
_version_	1724217849661095936

Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy

Similar Items